<DOC>
	<DOCNO>NCT00073437</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness infliximab ( Remicade ) patient Chronic Sarcoidosis . Infliximab ( Remicade ) target specific proteins body 's immune system help control development inflammation help reduce painful disease .</brief_summary>
	<brief_title>A Study Infliximab Patients With Sarcoidosis</brief_title>
	<detailed_description>The purpose study evaluate safety effectiveness infliximab treatment subject sarcoidosis pulmonary involvement show symptoms disease even though currently treat medication . Patients receive either placebo , 3 mg/kg infliximab , 5 mg/kg infliximab infusion week 0 , 2 , 6 , 12 , 18 , 24 . Safety evaluation perform specify interval throughout study consist laboratory test , vital sign ( blood pressure ) , physical examination occurrence severity adverse event well study specific procedure . Patients receive infusion Infliximab ( Remicade ) 3 5 mg/kg placebo week 0 , 2 , 6 , 12 , 18 24 .</detailed_description>
	<mesh_term>Sarcoidosis</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Patients must diagnose sarcoidosis least 1 year prior entry study Patients must laboratory test diagnose sarcoidosis prior screen Patients must diagnosis sarcoidosis chest x ray Patients must use investigational drug within 1 month prior enter study Patients must receive previous administration treatment therapeutic agent target reduce TNF pentoxifylline , thalidomide , etanercept , CDP 870 , adalimumab , within 3 month prior screen Patients must receive vaccination within 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Sarcoidosis</keyword>
	<keyword>Infliximab</keyword>
	<keyword>Pulmonary involvement</keyword>
	<keyword>Remicade</keyword>
</DOC>